Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014.
The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients.
Hematoncology Division, European Institute of Oncology, Milan, Italy.
Alberto
A
Agazzi
PD-1 inhibitors; chimeric antigen receptors; intensive chemotherapy; target therapy